Business
biOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders
biOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\nbiOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders\n\nbiOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders\n\n\nNew Board nominees include accomplished biopharmaceutical executives \n\n\nNancy Stagliano, Ph.D., CEO at True North Therapeutics; Deborah Rathjen, Ph.D., CEO & Managing Director of Bionomics; and Maha Radhakrishnan, M.D., SVP & Head of World Wide Medical at Bioverativ Therapeutics Inc.\n\n\nbiOasis Founder Mr. Rob Hutchison will step down as Chairman of the Board on Dec. 31, 2017\n\n VANCOUVER, BC--(Marketwired - August 28, 2017) - BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF)(TSX VENTURE: BTI) is pleased to announce its slate of nominees to the board of directors (the \"Board\") for election at the annual general meeting of shareholders (the \"Meeting\") on Thurs., Sept. 21, 2017. The slate is comprised of four current directors and three new nominees. The biOasis management team has nominated accomplished biopharmaceutical executives Nancy Stagliano, Ph.D., Deborah Rathjen, Ph.D. and Maha Radhakrishnan, M.D. for election to the Board at the Meeting. biOasis founder Mr. Rob Hutchison will step down as chairman of the board on Dec. 31, 2017. \"Rob has shown himself to be a real visionary, acquiring and securing new biOasis intellectual property (IP). He afforded the inception of biOasis in 2007, and led the company through April 2017. He has invested a great deal both personally and professionally into the company's success and we would not be where we are today without his business insights, IP expertise and knowledge of the Canadian markets,\" said Mark Day, Ph.D., president and chief executive officer, biOasis. \"I am indebted to Rob for the opportunity to lead this organization and for the guidance and support he has given me since I started with biOasis. Rob created a company with a unique collaborative phenotype, a key ingredient to success.\"\"Transitions like this are bittersweet, but I am confident this is the right time to begin to take this next step for biOasis' future. Mark is a dynamic CEO who I believe will continue to lead the Company upward and implement successful growth driven by the new dual business strategy, \" said Rob Hutchison, fou...